Section 2. Exercise-Induced Bronchospasm: Albuterol versus Montelukast: Highlights of the Asthma Summit 2009: Beyond the Guidelines. (Record no. 4156)
[ view plain ]
000 -LEADER | |
---|---|
fixed length control field | 02157nam a22003377a 4500 |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
fixed length control field | 190314s20102010 xxu||||| |||| 00| 0 eng d |
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
International Standard Serial Number | 1939-4551 |
024 ## - OTHER STANDARD IDENTIFIER | |
Standard number or code | 10.1097/WOX.0b013e3181d25eac [doi] |
024 ## - OTHER STANDARD IDENTIFIER | |
Standard number or code | 1939-4551-3-2-23 [pii] |
024 ## - OTHER STANDARD IDENTIFIER | |
Standard number or code | PMC3651111 [pmc] |
040 ## - CATALOGING SOURCE | |
Original cataloging agency | Ovid MEDLINE(R) |
099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) | |
PMID | 24228852 |
245 ## - TITLE STATEMENT | |
Title | Section 2. Exercise-Induced Bronchospasm: Albuterol versus Montelukast: Highlights of the Asthma Summit 2009: Beyond the Guidelines. |
251 ## - Source | |
Source | World Allergy Organization Journal. 3(2):23-30, 2010 Feb 15. |
252 ## - Abbreviated Source | |
Abbreviated source | World Allergy Organiza. journal. 3(2):23-30, 2010 Feb 15. |
253 ## - Journal Name | |
Journal name | The World Allergy Organization journal |
260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
Year | 2010 |
260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
Manufacturer | FY2010 |
265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE] | |
Publication status | epublish |
266 ## - Date added to catalog | |
Date added to catalog | 2019-03-14 |
520 ## - SUMMARY, ETC. | |
Abstract | Exercise-induced bronchospasm (EIB) involves airway obstruction with an onset shortly after exercising. It can occur in individuals without a diagnosis of asthma, but is most common in asthmatic patients (and in this scenario may be referred to as exercise-induced asthma, EIA), correlating with the patient's degree of airway hyperreactivity. While albuterol is the most commonly used rescue and prophylactic medication for EIB, the leukotriene antagonist, monetlukast, may be an appropriate choice for some patients. Clinical data have shown that once-daily treatment with montelukast (5 or 10 mg tablet) can offer protection against EIB within 3 days for some patients. Such an approach might be preferred for patients who have difficulty with inhaled medications and for children who cannot access their inhalers during the school day. Montelukast also may be an option to reduce side effects associated with albuterol for individuals who exercise regularly. |
546 ## - LANGUAGE NOTE | |
Language note | English |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | PubMed-not-MEDLINE -- Not indexed |
651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME | |
Institution | MedStar Washington Hospital Center |
656 ## - INDEX TERM--OCCUPATION | |
Department | Medicine/Pulmonary-Critical Care |
657 ## - INDEX TERM--FUNCTION | |
Medline publication type | Journal Article |
700 ## - ADDED ENTRY--PERSONAL NAME | |
Local Authors | Colice, Gene |
790 ## - Authors | |
All authors | Calhoun WJ, Colice G |
856 ## - ELECTRONIC LOCATION AND ACCESS | |
DOI | <a href="https://dx.doi.org/10.1097/WOX.0b013e3181d25eac">https://dx.doi.org/10.1097/WOX.0b013e3181d25eac</a> |
Public note | https://dx.doi.org/10.1097/WOX.0b013e3181d25eac |
942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
Koha item type | Journal Article |
Item type description | Article |
Withdrawn status | Lost status | Damaged status | Not for loan | Collection | Home library | Current library | Date acquired | Total Checkouts | Full call number | Barcode | Date last seen | Price effective from | Koha item type |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MedStar Authors Catalog | MedStar Authors Catalog | 03/14/2019 | 24228852 | 24228852 | 03/14/2019 | 03/14/2019 | Journal Article |